Swiss biopharma technology · Basel
BioXion is a Swiss biopharma development intelligence company connecting six intelligence modules - Program Development, Partner Programs, Quality, Analytical, Supply Chain and Regulatory - with cross-module visibility so teams can see risk earlier and act with more context.
Why BioXion exists
Critical evidence already exists - across teams, partners and validated systems. BioXion connects the six functional intelligence areas that shape program and lifecycle decisions, while keeping expert judgement and source systems central.
One module with route-specific planning: Novel Programs is live in v1.0; Biosimilars and Generics expand Program Development in Phase 2.
Partner governance across tech transfer, method transfer, manufacturing, testing, workstreams, dependencies and commitments.
Visibility into deviations, CAPA-related signals, complaints and follow-up without replacing validated QMS workflows.
Method lifecycle context, trending, anomaly signals and method-transfer risk connected to broader program decisions.
Future lifecycle visibility across supply, inventory, cold-chain and operational dependencies that can affect program continuity.
Future regulatory alignment and gap visibility linking relevant FDA, EMA and ICH context to active development programs.
Program Intelligence provides the Program Development-linked view; Lifecycle Intelligence connects signals across modules. AI supports risk detection, readiness scoring and explainable, traceable analysis rather than replacing expert judgement.
Program Development architecture
Program Development uses a shared intelligence backbone for program structure, readiness, lifecycle context and AI-supported decision making. The route inside that module changes to match the evidence model and regulatory pathway of the product being developed.
For original and innovative products across BioXion’s supported therapeutic modalities, with phase-, modality- and market-specific development roadmaps from preclinical through commercial and post-approval lifecycle.
A reference-product-led route built around the totality of evidence, including analytical and functional similarity, residual uncertainty, comparative development and market-specific biosimilar requirements.
A dedicated small-molecule generic route focused on API and drug-product CMC, formulation and dissolution strategy, stability, bioequivalence or biowaiver planning and abbreviated submission pathways.
Novel Programs, Biosimilars and Generics remain inside one Program Development module. They share the same enterprise architecture, Program Intelligence, lifecycle context and cross-module connections while applying route-specific milestones, evidence expectations and regulatory logic.
Connected intelligence
BioXion’s six modules provide the functional intelligence foundation. Program Intelligence, Lifecycle Intelligence, BioXion Connect and the Partner Intelligence Network connect that foundation across programs, partners and decisions - without turning BioXion into a validated system of record.
Two complementary dashboards give teams the right level of context depending on how BioXion is configured.
BioXion Connect is designed to let sponsors and CDMOs share program-relevant visibility while authoritative records remain in validated source systems.
PIN extends Partner Programs from oversight into partner discovery and structured qualification.
Company
BioXion was created from hands-on experience with the practical friction of biopharma development: fragmented program information, outsourced work spread across partners, and critical risks that become visible too late. The company is being built around one focused proposition: connect development intelligence without asking customers to replace the validated systems they already rely on.
The full platform architecture spans Program Development, Partner Programs, Quality, Analytical, Supply Chain and Regulatory. Within Program Development, BioXion uses three development routes: Novel Programs, Biosimilars and Generics. Program Intelligence and Lifecycle Intelligence provide dedicated views across the wider architecture, while AI adds risk detection, readiness scoring and traceable decision support across the platform.
BioXion began as a practical response to recurring development, partner and information-fragmentation problems experienced across biopharma programs.
BioXion v1.0 is live with the Novel Programs route inside Program Development, together with the Program Intelligence Dashboard and AI Insight in a Swiss-hosted environment.
Add Biosimilars and Generics as dedicated Program Development routes alongside Partner Programs, Quality and Analytical Intelligence, while deepening cross-module Lifecycle Intelligence and enterprise adoption. Supply Chain and Regulatory follow on the wider roadmap.
Partnerships
BioXion is designed for the realities of biopharma and CDMO development. We collaborate selectively with organisations that can help validate the product, shape workflows, strengthen integrations and scale commercial adoption.
Biopharma and CDMO teams helping validate workflows, usability and real-world decision value.
Integration, cloud and enterprise-technology relationships that strengthen deployment and interoperability.
Strategic relationships supporting market access, customer development and international expansion.
Capital partners aligned with a focused, enterprise biopharma software business and a disciplined product roadmap.
Leadership
BioXion’s founding team combines biopharma development experience, scientific research, product strategy and international commercial expertise.
Biopharma leader with 15+ years of international industry experience across external quality, analytical systems, development operations and cross-functional program execution. Sinisa founded HTS and leads BioXion product strategy and long-term corporate direction. His ongoing PhD research in Medical Sciences - Pharmacy focuses on formulation of biologics and vaccines, including predictive stability, molecular dynamics, protein interactions, lyophilisation and advanced delivery-system considerations.
Biotech and pharma commercial leader with a medical and scientific research background. Alexandros’ doctoral work spans medicine, pathology and nuclear medicine, including research on vitamin D in systemic disease and HPV in malignant melanoma. He leads go-to-market strategy, strategic partnerships, customer development and international business growth, connecting BioXion’s product proposition with industry needs and long-term market expansion.
BioXion · Basel, Switzerland
We are open to conversations with biopharma organisations, CDMOs, strategic partners and investors interested in BioXion’s next stage of growth.